In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed...
In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD)...
On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the type II RAF inhibitor tovorafenib (Ojemda) for patients 6 months of age...
On April 23, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older...
Recently, the U.S. Food and Drug Administration (FDA) approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative...
Nearly three-quarters of patients with breast cancer (73%) reported using at least one type of complementary medicine after cancer diagnosis, while surveyed oncologists believed that less than half (43%) of patients were using these approaches during cancer care. These and other findings from a...
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous daratumumab to pomalidomide/dexamethasone in patients with previously treated multiple myeloma....
Immunotherapy following surgery significantly improved disease-free survival compared to placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to results from the international phase III KEYNOTE-564 study presented at the 2021 ASCO Annual Meeting by Toni K....
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
In a study reported in JCO Oncology Practice, Manali I. Patel, MD, MPH, and colleagues found that a lay health worker–led intervention was associated with improved documentation of goals of care, increased clinical trial participation, and increased use of palliative care in a population of...
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...